Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid ® -ineligible patients, representing a significant population with few effective treatment options Final data analysis to be reported in January 2026 NEWTOWN, Pa.,

#TRAW Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

www.stocktitan.net/news/TRAW/traws-pharma-r...

🚀 Exciting times for #TRAW! Trading at $2.65, it's riding a bullish wave with RSI at 74.5 and MACD in the green. Above its 10 & 20-day SMAs, this stock's got momentum! Consider going LONG at $2.60, aiming for $2.80-$3.00. Stay sharp on market trends! 📈 #FeetrAI

🚀 Exciting times for #TRAW! Trading at $2.645, it's above key MAs with a bullish MACD and RSI of 72.5. Despite low volume, it broke resistance, hinting at more gains. Consider entering at $2.64, targeting $2.75 & $2.85. Stop loss: $2.55. Stay tuned for news! 📈 #FeetrAI

This is prabha this is for every News channel's globally

#delhi #chennai #india #WashingtonDC #winter #WINTER #TamilNews #America #traw #raftaar #emiway #ChennaiRains #bjp #congress #Democrats #Republicans #canada #lilireinhart #cole

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov.

#TRAW Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

www.stocktitan.net/news/TRAW/traws-pharma-r...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials Traws Pharma (NASDAQ: TRAW) advanced ratutrelvir into Phase 2 and secured extended CMC support from ChemDiv for API and drug product process research, scale-up, and analytical work. The first Phase 2 patient was dosed in October 2025 and top-line data are expected by year-end 2025. Ratutrelvir is a ritonavir-free Mpro (3CL) inhibitor developed by ChemDiv using Molsoft design and Expert Systems predictive pharmacology, designed for high potency across native and resistant SARS-CoV-2 strains and a 10-day, once-daily regimen.Expert Systems is extending its contract to provide AI-enabled predictive safety pharmacology to support clinical progression and regulatory readiness.

#TRAW ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

www.stocktitan.net/news/TRAW/chem-div-exten...

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single-arm trial assessing safety and efficacy in PAXLOVID ® -ineligible subjects, who

#TRAW Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

www.stocktitan.net/news/TRAW/traws-pharma-d...

This is prabha from India and quantummania.. join whatsapp group to read my 11 journals
#colesprouse #lilireinhart #emmawatson #koreanmodel #IndianEconomy #IndianArmy #louisiana #mumbai #rajakumari #raftaar #divine #traw #kodakblack
#koreatravel #london #tamilnadu #newyork #india #chennai #delhi

Potential PAXLOVID Competitor: Traws Pharma's Once-Daily COVID Drug Enters Phase 2 Trials Against $427M Market Biotech firm advances ritonavir-free COVID treatment ratutrelvir in two Phase 2 trials vs PAXLOVID ($427M Q2 sales). Studies target disease rebound, Long COVID prevention in broader patient population.

#TRAW Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

www.stocktitan.net/news/TRAW/traws-pharma-r...

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights Traws Pharma (NASDAQ: TRAW) reported Q2 2025 financial results and provided updates on its antiviral programs. The company ended Q2 with $13.1 million in cash, reporting revenue of $2.7 million and a net loss of $0.9 million ($0.11 per share).Key developments include the prioritization of ratutrelvir, a ritonavir-free protease inhibitor for COVID-19 treatment, with Phase 2 studies planned to begin soon. The company is also advancing Tivoxavir Marboxil (TXM) for influenza, focusing on stockpiling readiness with BARDA.Management changes include Jack Stover as new Board Chairman and Charles Parker as Interim CFO. The company will evaluate ratutrelvir versus PAXLOVID® in Phase 2 trials, with results expected by year-end 2025.

#TRAW Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

www.stocktitan.net/news/TRAW/traws-pharma-r...

Journal about World war politics and aliens.....

Prabha

#nasa #isro #delhi #chennai #india #losangeles #WashingtonDC #mumbai
#tamilnadu #WWERaw    #traw #Colesprouse #lilireinhart #EmmaWatson #russia #usa #worldwar #aliens #annamalai #rahulgandhi #TamilCinema #european

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions Traws Pharma (NASDAQ: TRAW) has announced multiple regulatory submissions advancing its antiviral pipeline. The company has submitted a Phase 2 protocol to HREC for tivoxavir marboxil (TXM) to evaluate its effectiveness against both seasonal and bird flu in the Southern Hemisphere. Additionally, briefing documents were submitted to the FDA for a Type D meeting regarding potential accelerated approval of TXM for bird flu treatment.The company has also submitted a Phase 2 study protocol to HREC for ratutrelvir, their protease inhibitor that doesn't require ritonavir co-administration, to evaluate its effectiveness against COVID-19. This study will compare ratutrelvir to PAXLOVID® in newly diagnosed patients, with specific focus on disease rebound and Long COVID development. The study includes a separate arm for patients ineligible for PAXLOVID® treatment.The TXM study will be conducted in Australia and Southeast Asian countries with high rates of human bird flu infections, while the ratutrelvir study will evaluate patients on a 10-day treatment regimen compared to PAXLOVID's® 5-day regimen.

#TRAW Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

www.stocktitan.net/news/TRAW/traws-pharma-a...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Tue Jun 3rd - #YGMZ #SRBK #NTCL #WIMI #TRAW #SOHU #MPB #LX #IMMP #ETCN #CTRM #ASTH #QD #PX #PBT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V $3 Undercard Surge – More Stocks Inside! Getting your Trinity Audio player ready... From $30 million Solana, Bitcoin staking and rare cancer breakthroughs to critical minerals exploration and transformative mergers, these companies—are resha...

#NIVF, #TRAW, #KPRX #PNPNF #PNPN
thestreetreports.com/mag-8-moment...

Breakthrough: New Drug Shows Unprecedented 80% Success Rate in Rare Skin Cancer Trial First clinical trial achieves 50% complete response in rare RDEB skin cancer. Traws Pharma seeks development partners for promising oncology asset. Learn full results.

#TRAW Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

www.stocktitan.net/news/TRAW/traws-pharma-a...

FDA Advances Critical Bird Flu Drug Development as Ex-CDC Chief Warns of 50% Death Rate Risk FDA provides pathway for Traws Pharma's dual bird flu/seasonal flu treatment. Ex-CDC director pushes for urgent pandemic stockpiling. See development timeline.

#TRAW Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

www.stocktitan.net/news/TRAW/traws-pharma-a...

Traws Pharma Earnings Surge to $21.5M as Former CDC Director Backs Novel Flu and COVID Drug Pipeline Q1 earnings reveal $21.5M profit while advancing two breakthrough antiviral programs. Ex-CDC Director Redfield validates development strategy. See pipeline milestones.

#TRAW Traws Pharma Reports First Quarter 2025 Results and Business Highlights

www.stocktitan.net/news/TRAW/traws-pharma-r...

Traws Pharma Reports Full Year 2024 Results and Business Highlights Traws Pharma (NASDAQ: TRAW) reported its full year 2024 financial results and business updates. The company's lead product candidate, tivoxavir marboxil (TXM), showed promising results in bird flu treatment through three animal models and Phase 1 data. The company is pursuing potential accelerated approval via FDA's 'Animal Rule'.Financial highlights include: Cash position of $21.3 million as of December 31, 2024R&D expenses increased to $12.8 million from $11.4 million in 2023G&A expenses rose to $12.3 million from $9.1 million in 2023Net loss of $166.5 million ($35.21 per share) compared to $18.9 million in 2023The company completed a $20 million financing in December 2024 and expects its cash runway to extend into Q1 2026. CEO Werner Cautreels will retire effective March 31, 2025, with Chairman Iain D. Dukes assuming the role of Interim CEO.

#TRAW Traws Pharma Reports Full Year 2024 Results and Business Highlights

www.stocktitan.net/news/TRAW/traws-pharma-r...

Leadership Shift at Traws Pharma: Chairman Steps Up as CEO Exits, Key Antiviral Programs Continue Executive Chairman assumes interim CEO role as Werner Cautreels retires. Former CEO stays on board, advising two clinical-stage antiviral programs. Full transition details inside.

#TRAW Traws Pharma Announces Management Updates

www.stocktitan.net/news/TRAW/traws-pharma-a...

Breakthrough: Next-Gen COVID Drug Defeats 18 Variants Without Ritonavir Boost Novel protease inhibitor demonstrates efficacy against resistant COVID variants without ritonavir. Phase 1 success paves way for Phase 2 trials. Full analysis inside.

#TRAW Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR

www.stocktitan.net/news/TRAW/traws-pharma-s...

Breakthrough: New Bird Flu Drug Achieves Remarkable 99.9% Viral Reduction in Latest Primate Tests Single-dose antiviral dramatically cuts H5N1 viral load in primates, positioning for fast-track FDA review. Latest data strengthens path to human trials. Full analysis inside.

#TRAW Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates

www.stocktitan.net/news/TRAW/traws-pharma-a...

Breakthrough: Revolutionary Bird Flu Drug Achieves Perfect Survival Rate in Latest Trial Data Traws Pharma's Tivoxavir Marboxil demonstrates 3-week efficacy with single dose against resistant flu strains. FDA acceleration pathway discussion upcoming. Full data March 31.

#TRAW Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

www.stocktitan.net/news/TRAW/traws-pharma-s...

Can Traws Pharma's Single-Dose Treatment Combat the Growing Bird Flu Threat? Single-dose antiviral demonstrated increased survival and reduced viral presence in ferrets infected with H5N1. Company pursuing FDA's 'Animal Rule' for accelerated approval.

#TRAW Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

www.stocktitan.net/news/TRAW/traws-pharma-r...

Traws Pharma's Bird Flu Drug Shows Promise in Phase I Safety Trial, Targets H5N1 Prevention Tivoxavir marboxil demonstrates safety and positive pharmacokinetics as one-dose H5N1 therapy. Preclinical data shows effectiveness against resistant strains amid rising bird flu concerns.

#TRAW Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

www.stocktitan.net/news/TRAW/traws-pharma-a...

Breakthrough: Ex-CDC Chief Backs Traws Pharma's Single-Dose Bird Flu Drug After Promising Trial Traws Pharma's Tivoxavir Marboxil shows 23-day effectiveness from single dose in Phase 1 trials, with former CDC Director highlighting urgent need amid bird flu concerns.

#TRAW Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

www.stocktitan.net/news/TRAW/expert-systems...

Traws Pharma's Bird Flu Drug Shows Breakthrough Results in Phase 1 Trial, Achieves 23-Day Protection Traws Pharma's tivoxavir marboxil demonstrates promising clinical data against H5N1, with sustained protection and complete survival rates in preclinical studies.

#TRAW Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

www.stocktitan.net/news/TRAW/traws-pharma-a...